Mylod%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at

## Overview Mylotat is a brand name for **atracurium besylate**, a non-depolarizing neuromuscular blocker. It is used to facilitate endotracheal intubation, provide skeletal muscle relaxation for surgery, and aid mechanical ventilation. ## Primary Indications * Adjunct to general anesthesia to facilitate endotracheal intubation. * Adjunct to general anesthesia to provide skeletal muscle relaxation during surgery. * Facilitation of mechanical ventilation in intensive care unit (ICU) patients. ## Adult Dosing * **Intubation:** 0.4 to 0.5 mg/kg intravenously (IV) as a single bolus. Onset is typically within 2-3 minutes. * **Maintenance:** 0.08 to 0.1 mg/kg IV given as needed to maintain neuromuscular blockade. * **Continuous Infusion (ICU):** Typically initiated at 5 to 10 mcg/kg/minute once neuromuscular block is established, then adjusted based on clinical response or monitoring. Usual range is 3 to 20 mcg/kg/minute. ## Pediatric Dosing Dosing in pediatric patients can be variable and requires careful monitoring. * **Neonates (< 1 month):** Higher sensitivity; doses may need to be lower, and prolonged blockade may occur. * **Infants (1-24 months):** May require higher initial doses (e.g., 0.3-0.4 mg/kg IV) and maintenance infusions. * **Children (2-12 years):** Dosing is similar to adults (0.4-0.5 mg/kg IV for intubation). **Note:** Specific pediatric dosing should be guided by institutional protocols and careful patient assessment. ## Dose Adjustments * **Hepatic or Renal Impairment:** Atracurium undergoes Hofmann elimination and ester hydrolysis, which are independent of liver and kidney function. Therefore, dose adjustments are generally *not* required in these patient populations, although prolonged effects may be observed due to altered metabolism and distribution of other drugs. * **Elderly Patients:** May exhibit increased sensitivity and a longer duration of action. Lower initial doses may be considered. * **Temperature:** Hypothermia can prolong the duration of action. Hyperthermia may shorten it. ## Contraindications * Known hypersensitivity to atracurium or its components. ## Adverse Effects * **Common:** Transient hypotension, bronchospasm, rash, pruritus, urticaria. * **Serious:** Profound muscle weakness leading to respiratory depression or apnea, anaphylaxis. * **Histamine Release:** Atracurium can cause dose-related histamine release, leading to flushing, bronchospasm, and hypotension. ## Key Drug Interactions * **Inhaled Anesthetics:** Can potentiate neuromuscular blockade and prolong duration. * **Antibiotics:** Certain antibiotics (e.g., aminoglycosides, polymyxins, clindamycin, tetracyclines) can potentiate neuromuscular blockade. * **Diuretics:** Can also potentiate neuromuscular blockade. * **Local Anesthetics:** May potentiate neuromuscular blockade. * **Magnesium Sulfate:** Can potentiate neuromuscular blockade. * **Neuromuscular Blocking Agents:** Use with other agents requires caution and appropriate monitoring. * **Succinylcholine:** Use before or after atracurium requires careful consideration of potential effects on the duration and intensity of blockade. ## Monitoring * **Clinical signs of neuromuscular blockade:** Observe for muscle twitching, presence of spontaneous respirations, and ability to follow commands. * **Train-of-four (TOF) monitoring:** Preferred method to quantify neuromuscular blockade and guide dosing, especially for maintenance infusions or in the ICU. A TOF count of 0-1 is typically desired for intubation, and TOF counts of 1-2 may be targeted for mechanical ventilation. * **Hemodynamic parameters:** Monitor blood pressure and heart rate for signs of hypotension or bronchospasm, particularly during administration. ## Clinical Pearls * Atracurium's degradation via Hofmann elimination makes its duration of action less dependent on organ function compared to other neuromuscular blockers, which can be advantageous in patients with renal or hepatic insufficiency. * The potential for histamine release necessitates careful administration and monitoring for signs of bronchospasm and hypotension. Administration over 60 seconds can help mitigate this. * Recovery from atracurium can be variable. Reversal with anticholinesterase agents (e.g., neostigmine, pyridostigmine) may be necessary, but caution is advised in patients with prolonged blockade. **Disclaimer:** This information is intended for clinical decision support and does not replace the official prescribing information or institutional protocols. Always verify current prescribing information and consult with a qualified healthcare professional before making any treatment decisions.